Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company’s Board of Directors, effective January 1, 2024. Mr. Luther will replace Matt Angel, Ph.D., the current President and Chief Executive Officer.
Related news for (ERNA)
- Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
- Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
- Eterna Therapeutics Announces Expansion of Scientific Advisory Board
- Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
- 24/7 Market News Snapshot 14 January, 2025 – Eterna Therapeutics Inc. Common Stock (NASDAQ:ERNA)